HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
The USFDA has issued 5 observations pursuant to the completion of audit
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)